Dr. Herman Waldmann
Scientific Advisory Board Member
Former Department Head and Professor Emeritus of Pathology at the Oxford Medical School and Clinical Director of Oxford’s Therapeutic Antibody Centre
Dr. Waldmann gained his BA, MD and PhD at Cambridge, where he was also Professor of Therapeutic Immunology. He is a key figure in the field of immune system regulation. A past winner of the prestigious Starzl Prize in Surgery and Immunology from the Starzl Transplantation Institute at the University of Pittsburg, Dr. Waldmann received a SCRIP Lifetime Achievement Award, one of the most prestigious awards in the biotechnology industry. His pioneering work in monoclonal antibodies led to the development of Lemtrada, a Multiple Sclerosis treatment developed by Genzyme (Sanofi) with 2018 sales exceeding $450 million.